1. Home
  2. RVMDW vs RBBN Comparison

RVMDW vs RBBN Comparison

Compare RVMDW & RBBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • RBBN
  • Stock Information
  • Founded
  • RVMDW N/A
  • RBBN 1997
  • Country
  • RVMDW United States
  • RBBN United States
  • Employees
  • RVMDW 490
  • RBBN N/A
  • Industry
  • RVMDW
  • RBBN EDP Services
  • Sector
  • RVMDW
  • RBBN Technology
  • Exchange
  • RVMDW Nasdaq
  • RBBN Nasdaq
  • Market Cap
  • RVMDW N/A
  • RBBN N/A
  • IPO Year
  • RVMDW N/A
  • RBBN 2000
  • Fundamental
  • Price
  • RVMDW $0.38
  • RBBN $3.90
  • Analyst Decision
  • RVMDW
  • RBBN Strong Buy
  • Analyst Count
  • RVMDW 0
  • RBBN 2
  • Target Price
  • RVMDW N/A
  • RBBN $5.75
  • AVG Volume (30 Days)
  • RVMDW N/A
  • RBBN 339.0K
  • Earning Date
  • RVMDW N/A
  • RBBN 10-23-2024
  • Dividend Yield
  • RVMDW N/A
  • RBBN N/A
  • EPS Growth
  • RVMDW N/A
  • RBBN N/A
  • EPS
  • RVMDW N/A
  • RBBN N/A
  • Revenue
  • RVMDW N/A
  • RBBN $808,923,000.00
  • Revenue This Year
  • RVMDW N/A
  • RBBN $1.98
  • Revenue Next Year
  • RVMDW N/A
  • RBBN $5.53
  • P/E Ratio
  • RVMDW N/A
  • RBBN N/A
  • Revenue Growth
  • RVMDW N/A
  • RBBN N/A
  • 52 Week Low
  • RVMDW N/A
  • RBBN $2.05
  • 52 Week High
  • RVMDW N/A
  • RBBN $4.31
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • RBBN 56.62
  • Support Level
  • RVMDW N/A
  • RBBN $3.69
  • Resistance Level
  • RVMDW N/A
  • RBBN $4.10
  • Average True Range (ATR)
  • RVMDW 0.00
  • RBBN 0.16
  • MACD
  • RVMDW 0.00
  • RBBN -0.03
  • Stochastic Oscillator
  • RVMDW 0.00
  • RBBN 39.71

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: